文献速递神经肿瘤

难治性侵袭性垂体大泌乳素瘤早期识别并启动替莫唑胺化疗实现长期持续缓解

Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
PubMed 文献 · World Neurosurg · 2018-07-18

本文报告一例56岁男性侵袭性难治性大泌乳素瘤,长期多巴胺激动剂、立体定向放射外科及多次经蝶手术均失败,持续高泌乳素血症和肿瘤进展。启动替莫唑胺治疗11个周期后,泌乳素从696 ng/mL降至15.2 ng/mL,肿瘤体积缩小>90%;停化疗近6年仍持续缓解(泌乳素3.1 ng/mL),仅需卡麦角林1.5 mg/周,无影像学或临床复发证据。作者认为替莫唑胺对医学和手术难治的侵袭性非典型泌乳素瘤有效,鼓励将其作为第四线治疗,尤其提倡早期使用。

要点

  • 替莫唑胺治疗11个周期后泌乳素由696 ng/mL降至15.2 ng/mL,肿瘤体积缩小>90%。
  • 停化疗近6年持续缓解,泌乳素3.1 ng/mL,仅需卡麦角林1.5 mg/周,无复发证据。
  • 作者鼓励将替莫唑胺作为难治复发侵袭性泌乳素瘤第四线治疗,尤其提倡早期使用。

核心结论

  • 作者认为替莫唑胺对医学和手术难治的侵袭性非典型泌乳素瘤有效,可使泌乳素正常化并控制肿瘤大小。
  • 作者鼓励将替莫唑胺作为多巴胺激动剂、经蝶手术和放疗之后的第四线治疗用于难治复发侵袭性泌乳素瘤,尤其提倡对侵袭性且其他治疗难治的泌乳素瘤早期使用。

研究设计与样本

  • 个案报告:1例56岁男性侵袭性难治性大泌乳素瘤,长期多巴胺激动剂、立体定向放射外科及多次经蝶手术切除均失败。

主要发现

  • 替莫唑胺治疗11个周期期间,泌乳素从696 ng/mL降至15.2 ng/mL,肿瘤体积缩小>90%。
  • 停化疗近6年持续缓解,泌乳素3.1 ng/mL,仅需卡麦角林1.5 mg/周,无影像学或临床肿瘤复发证据。

临床怎么用

  • 作者鼓励将替莫唑胺纳入难治、复发和侵袭性泌乳素瘤的管理,作为多巴胺激动剂治疗、经蝶切除和放疗之后的第四线治疗策略。
  • 作者尤其提倡对侵袭性且其他治疗难治的泌乳素瘤早期使用替莫唑胺。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Invasive, medically refractory, and multiply recurrent pituitary adenomas pose a rare, but nevertheless significant, challenge for conventional management modalities. Temozolomide (TMZ) has been reported to be useful as an adjunctive treatment for some patients. We describe the efficacy of TMZ when used early in the management of invasive prolactinoma. CASE DESCRIPTION: A 56-year-old man presented with an invasive, refractory macroprolactinoma for which long-term dopamine agonists, stereotactic radiosurgery, and multiple transsphenoidal surgical resections had failed. He had experienced persistent hyperprolactinemia and tumor progression. Thus, TMZ was started. During the 11 cycles of TMZ therapy, the patient's prolactin level decreased from 696 ng/mL to 15.2 ng/mL, with a >90% decrease in tumor size. Nearly 6 years after discontinuing chemotherapy, the patient remained in sustained remission (prolactin level, 3.1 ng/mL) requiring only 1.5 mg of cabergoline weekly, without radiographic or clinical evidence of tumor recurrence. CONCLUSIONS: We conclude that TMZ can be efficacious in the management of medically and surgically refractory, invasive atypical prolactinomas, resulting in normalization of the prolactin levels and control of the tumor size. We encourage the inclusion of TMZ in the management of refractory, recurrent, and invasive prolactinomas, as a fourth-line treatment strategy, after dopamine agonist treatment, transsphenoidal resection, and radiation therapy. We especially advocate the early use of TMZ for aggressive and otherwise refractory prolactinomas.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Barkhoudarian G, Palejwala SK, Ogunbameru R, et al. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission. World Neurosurg. 2018. PMID: 30031177. doi:10.1016/j.wneu.2018.07.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。